Skip to main content
Equibles
TBPH logo

TBPH · Theravance Biopharma, Inc. · Metrics

Track TBPH — free

Use TBPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TBPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$17.06 +0.00 (+0.00%) At close · Sep 9
Russell 2000 member Rebalance outlook locked
Market Cap
$886.77M
Shares
51.92M

TBPH metrics

73 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$17.06
Market cap
$886.77M

Price action

20 metrics
Price change (1W)
+0.2%
Price change (30D)
+0.9%
Price change (3M)
+3.5%
Price change (6M)
+21.6%
Price change (YTD)
-8.8%
Price change (1Y)
+22.6%
Trailing year
Price change (5Y)
+96.3%
52-week high
$20.74
52-week low
$13.57
Change from 52-week high
-17.7%
Change from 52-week low
+25.7%
Annualized volatility
45.1%
Annualized volatility (3M)
12.2%
Beta
0.6
RSI (14D)
61.0
Price vs SMA 50
+0.6%
Price vs SMA 200
-1.3%
Avg volume (3M)
643,007
Relative volume
0.4
Average dollar volume
$10.89M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
51.92M

Valuation

12 metrics
P / E (TTM)
16.9
Trailing earnings · reciprocal yield 5.9%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
8.5×
reciprocal yield 11.8%
P / book
3.1
reciprocal yield 32.7%
FCF yield
—
TTM · current market cap
Buyback yield
0.1%
P / FCF
—
P / operating cash flow
16.5
reciprocal yield 6.1%
Earnings yield
6.1%

Historical valuation

8 metrics
P / E historical average (3Y)
22.9×
reciprocal yield 4.4%
P / E historical average (5Y)
14.7×
reciprocal yield 6.8%
EV / revenue historical average (3Y)
16.8×
reciprocal yield 6.0%
EV / revenue historical average (5Y)
19.3×
reciprocal yield 5.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
—
Operating margin
-4.0%
Trailing 12 months
Net margin
51.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$4.20M
Net income (TTM)
$53.81M
Trailing 12 months
Diluted EPS (TTM)
$1.01
FCF margin
—
Effective tax rate
8.7%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.81

Growth

11 metrics
Revenue growth YoY
-20.9%
Year over year
Net income growth YoY
-110.8%
Revenue (TTM)
$104.31M
Trailing 12 months
EPS growth YoY
-110.2%
Shares change YoY
+1.9%
Year over year · more shares
Revenue CAGR (3Y)
+27.9%
Revenue CAGR (5Y)
+8.4%
EPS CAGR (3Y)
-44.2%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
18.6%
Return on assets
11.5%
Debt / equity
—
Current ratio
13.5
EBITDA (TTM)
−$243.97M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$219.77M
Total assets
$469.77M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$53.74M
Capital expenditures (TTM)
—
R&D (TTM)
$26.01M
SG&A (TTM)
$68.75M
Stock compensation (TTM)
$19.55M
R&D / revenue
24.9%
Stock compensation / revenue
18.7%

Ownership (13F)

3 metrics
13F filers
180
13F filer change QoQ
+5
Institutional ownership
92.8%

Short interest

3 metrics
Short interest
3.3%
Latest settlement · 2.5 days to cover
Days to cover
2.5d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$6.13M
Insider-sentiment score
23 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1583107 CUSIP G8807B106 13F (30d) 119 filings 118 filers Visit website Investor relations